IP Library Granted Patent US 8,563,004
Granted Patent B2
US 8,563,004 · App. 11/336,706 · Granted Oct 22, 2013

Patent

Inventors: Daryll A. Emery (New London, MN); Darren E. Straub (New London, MN); Laura Wonderling (Minneapolis, MN)
Assignee: Epitopix LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,563,004
App. No.
11/336,706
Granted
Oct 22, 2013
Kind
B2
Abstract

The present invention provides isolated polypeptides isolatable from a Yersinia spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.

Claims (26)

1. A composition comprising:

isolated polypeptides having molecular weights of 94 kDa, 88 kDa, 77 kDa, 73 kDa, and 64 kDa, wherein molecular weight is determined by electrophoresis on a sodium dodecyl sulfate-polyacrylamide gel, wherein the polypeptides having a molecular weight of 94 kDa, 88 kDa, 77 kDa, 73 kDa, and 64 kDa are expressed by a Yersinia pestis at a greater level when incubated in media comprising an iron chelator than when grown in the media without the iron chelator;

wherein the 94 kDa polypeptide has a mass fingerprint that includes polypeptide fragments having masses of 961.44, 1167.49, 1257.64, 1371.63, 1383.64, 1408.71, 1520.82, 1668.86, 1685.79, 1713.78, 1716.81, 1796.92, 1832.92, 1844.91, 2218.12, and 2426.09 Da;

wherein the 88 kDa polypeptide has a mass fingerprint that includes polypeptide fragments having masses of 888.51, 926.46, 945.53, 960.54, 1171.60, 1176.57, 1289.64, 1332.67, 1357.66, 1403.74, 1418.68, 1507.73, 1578.78, 1672.80, 1735.83, 2400.17, and 2665.28 Da;

wherein the 77 kDa polypeptide has a mass fingerprint that includes polypeptide fragments having masses of 686.37, 784.49, 858.41, 952.50, 1140.65, 1155.66, 1170.64, 1197.57, 1402.71, 1408.68, 1482.73, 1522.71, 1550.77, 1617.74, 1674.78, 1745.84, 1787.92, 1819.96, 1851.87, 1940.75, 2013.02, 2017.97, 2056.96, 2168.01, 2169.10, 2426.25, 2457.00, and 2828.33 Da;

wherein the 73 kDa polypeptide has a mass fingerprint that includes polypeptide fragments having masses of 628.39, 748.43, 909.42, 930.51, 1291.71, 1370.81, 1440.70, 1478.71, 1586.83, 1604.86, 1640.87, 1654.77, 1705.82, 1707.83, 1757.91, 1796.97, 1856.01, 1912.94, 2004.03, 2072.02, 2155.08, 2301.07, 2395.11, 2484.12, 2557.36, 2557.36, 2675.42, 2983.33, 3161.51, 3184.52, 3424.79, and 3471.62 Da; and

wherein the 64 kDa polypeptide has a mass fingerprint that includes polypeptide fragments having masses of 713.42, 759.42, 773.40, 806.41, 919.48, 1023.50, 1051.53, 1102.55, 1164.56, 1186.57, 1199.60, 1281.67, 1394.68, 1444.73, 1479.70, 1545.80, 1667.72, 1692.82, 1730.85, 1789.81, 1904.85, 1968.90, 1981.02, 2009.89, 2027.02, 2058.99, 2162.17, 2363.13, 2377.30, 2819.49, and 2929.46 Da.

2. The composition of claim 1 further comprising a pharmaceutically acceptable carrier.

3. The composition of claim 1 wherein the polypeptides are isolatable from Y. pestis strain KIM6+.

4. A composition comprising:

at least two isolated polypeptides, each polypeptide having a molecular weight of 94 kDa, 88 kDa, 77 kDa, 73 kDa, or 64 kDa, wherein molecular weight is determined by electrophoresis on a sodium dodecyl sulfate-polyacrylamide gel, wherein the polypeptides having a molecular weight of 94 kDa, 88 kDa, 77 kDa, 73 kDa, or 64 kDa are expressed by a Yersinia pestis at a greater level when incubated in media comprising an iron chelator than when grown in the media without the iron chelator, and wherein the at least two isolated polypeptides having molecular weights of 94 kDa, 88 kDa, 77 kDa, 73 kDa, or 64 kDa have seroreactive activity with convalescent serum from an animal infected with Y. pestis strain KIM6+;

wherein the 94 kDa polypeptide has a mass fingerprint that includes polypeptide fragments having masses of 961.44, 1167.49, 1257.64, 1371.63, 1383.64, 1408.71, 1520.82, 1668.86, 1685.79, 1713.78, 1716.81, 1796.92, 1832.92, 1844.91, 2218.12, and 2426.09 Da;

wherein the 88 kDa polypeptide has a mass fingerprint that includes polypeptide fragments having masses of 888.51, 926.46, 945.53, 960.54, 1171.60, 1176.57, 1289.64, 1332.67, 1357.66, 1403.74, 1418.68, 1507.73, 1578.78, 1672.80, 1735.83, 2400.17, and 2665.28 Da;

wherein the 77 kDa polypeptide has a mass fingerprint that includes polypeptide fragments having masses of 686.37, 784.49, 858.41, 952.50, 1140.65, 1155.66, 1170.64, 1197.57, 1402.71, 1408.68, 1482.73, 1522.71, 1550.77, 1617.74, 1674.78, 1745.84, 1787.92, 1819.96, 1851.87, 1940.75, 2013.02, 2017.97, 2056.96, 2168.01, 2169.10, 2426.25, 2457.00, and 2828.33 Da;

wherein the 73 kDa polypeptide has a mass fingerprint that includes polypeptide fragments having masses of 628.39, 748.43, 909.42, 930.51, 1291.71, 1370.81, 1440.70, 1478.71, 1586.83, 1604.86, 1640.87, 1654.77, 1705.82, 1707.83, 1757.91, 1796.97, 1856.01 1912.94, 2004.03, 2072.02, 2155.08, 2301.07, 2395.11, 2484.12, 2557.36, 2557.36, 2675.42, 2983.33, 3161.51, 3184.52, 3424.79, and 3471.62 Da; and

wherein the 64 kDa polypeptide has a mass fingerprint that includes polypeptide fragments having masses of 713.42, 759.42, 773.40, 806.41, 919.48, 1023.50, 1051.53, 1102.55, 1164.56, 1186.57, 1199.60, 1281.67, 1394.68, 1444.73, 1479.70, 1545.80, 1667.72, 1692.82, 1730.85, 1789.81, 1904.85, 1968.90, 1981.02, 2009.89, 2027.02, 2058.99, 2162.17, 2363.13, 2377.30, 2819.49, and 2929.46 Da.

5. The composition of claim 4 further comprising a pharmaceutically acceptable carrier.

6. The composition of claim 4 wherein the polypeptides are isolatable from Y. pestis strain KIM6+.

7. A composition comprising:

at least two isolated polypeptides, each polypeptide having a molecular weight of 88 kDa, 77 kDa, 73 kDa, or 64 kDa, wherein molecular weight is determined by electrophoresis on a sodium dodecyl sulfate-polyacrylamide gel, wherein the polypeptides having a molecular weight of 88 kDa, 77 kDa, 73 kDa, or 64 kDa are expressed by a Yersinia pestis at a greater level when incubated in media comprising an iron chelator than when grown in the media without the iron chelator;

wherein the isolated polypeptide with a molecular weight of 88 kDa comprises the amino acid sequences of SEQ ID NO:243, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO:246, SEQ ID NO:247, SEQ ID NO:248, SEQ ID NO:249, SEQ ID NO:250, SEQ ID NO:251, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:254, SEQ ID NO:255, SEQ ID NO:256, SEQ ID NO:257, SEQ ID NO:258, and SEQ ID NO:259;

wherein the isolated polypeptide with a molecular weight of 77 kDa comprises the amino acid sequences of SEQ ID NO:260, SEQ ID NO:261, SEQ ID NO:262, SEQ ID NO:263, SEQ ID NO:264, SEQ ID NO:265, SEQ ID NO:266, SEQ ID NO:267, SEQ ID NO:268, SEQ ID NO:269, SEQ ID NO:270, SEQ ID NO:271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282, SEQ ID NO:283, SEQ ID NO:284, SEQ ID NO:285, SEQ ID NO:286, and SEQ ID NO:287;

wherein the isolated polypeptide with a molecular weight of 73 kDa comprises the amino acid sequences of SEQ ID NO:288, SEQ ID NO:289, SEQ ID NO:290, SEQ ID NO:291, SEQ ID NO:292, SEQ ID NO:293, SEQ ID NO:294, SEQ ID NO:295, SEQ ID NO:296, SEQ ID NO:297, SEQ ID NO:298, SEQ ID NO:299, SEQ ID NO:300, SEQ ID NO:301, SEQ ID NO:302, SEQ ID NO:303, SEQ ID NO:304, SEQ ID NO:305, SEQ ID NO:306, SEQ ID NO:307, SEQ ID NO:308, SEQ DID NO:309, SEQ ID NO:310, SEQ ID NO:311, SEQ ID NO:312, SEQ ID NO:313, SEQ ID NO:314, SEQ ID NO:315, SEQ ID NO:316, SEQ ID NO:317, and SEQ ID NO:318; and

wherein the isolated polypeptide with a molecular weight of 64 kDa comprises the amino acid sequences of SEQ ID NO:319, SEQ ID NO:320, SEQ ID NO:321, SEQ ID NO:322, SEQ ID NO:323, SEQ ID NO:324, SEQ ID NO:325, SEQ ID NO:326, SEQ ID NO:327, SEQ ID NO:328, SEQ ID NO:329, SEQ ID NO:330, SEQ ID NO:331, SEQ ID NO:332, SEQ ID NO:333, SEQ ID NO:334, SEQ ID NO:335, SEQ ID NO:336, SEQ ID NO:337, SEQ ID NO:338, SEQ ID NO:339, SEQ ID NO:340, SEQ ID NO:341, SEQ ID NO:342, SEQ ID NO:343, SEQ ID NO:344, SEQ ID NO:345, SEQ ID NO:346, SEQ ID NO:347, SEQ ID NO:348, and SEQ ID NO:349.

8. The composition of claim 7 further comprising a pharmaceutically acceptable carrier.

9. The composition of claim 7 wherein the polypeptides are isolatable from Y. pestis strain KIM6+.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2024
From: EPITOPIX, LLC
To: VAXXINOVA US, INC.
Reel/Frame 066488/0734 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2010
From: WONDERLING, LAURA
To: SYNTIRON LLC
Reel/Frame 024423/0920 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2010
From: SYNTIRON LLC
To: EPITOPIX LLC
Reel/Frame 024425/0843 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2007
From: EMERY, DARYLL A.; STRAUB, DARREN E.; WONDERLING, LAURA (IN THE EMPLOY OF SYNTIRON, LLC); WONDERLING, LAURA (IN THE EMPLOY OF EPITOPIX, LLC)
To: EPITOPIX, LLC
Reel/Frame 019739/0908 →
Continuity (2)
Provisional Application 60646106 · Jan 21, 2005
Related Publication 20060269564A1 · Nov 30, 2006